医学
前列腺癌
前列腺
肿瘤科
神经内分泌分化
谷氨酸羧肽酶Ⅱ
内科学
激素疗法
泌尿科
癌症
作者
Ediz Beyhan,Özge Erol Fenercioğlu,Rahime Şahin,Tevfik Fikret Çermik,Nurhan Ergül
标识
DOI:10.1097/rlu.0000000000005131
摘要
ABSTRACT: We present an 87-year-old man diagnosed with prostate cancer and neuroendocrine differentiation, posttherapy results to consecutive 177 Lu-prostate-specific membrane antigen and 177 Lu-DOTATATE. Despite hormonal therapy and chemoradiotherapy, the patient progressed rapidly, and multiple liver and bone metastases showed regression after 177 Lu-prostate-specific membrane antigen and 177 Lu-DOTATATE treatment. Prostate cancer with neuroendocrine differentiation is resistant to treatments; however, treatment with the combination of 177 Lu-DOTATATE therapy may be promising.
科研通智能强力驱动
Strongly Powered by AbleSci AI